Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.
A consequential new lawsuit could force J&J to be held liable for allegedly overpaying for workers' drugs, through its PBM.
A Democrat was willing to sign on to legislation that would weaken Medicare's power to negotiate drug prices, a key Biden achievement.
Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of a placebo group.
As a doctor who treats people with Alzheimer’s, I don’t blame Biogen for the Aduhelm mess. I blame the FDA.
The Swiss drug giant will be happy to pay a small breakup fee to MorphoSys to avoid owning a drug that regulators will turn away.
